U.S. Markets open in 4 hrs 40 mins

Intec Pharma Ltd (NTEC)

NasdaqCM - NasdaqCM Real Time Price. Currency in USD
Add to watchlist
3.2900+0.0400 (+1.23%)
At close: 4:00PM EST
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Neutralpattern detected
Previous Close3.2500
Open3.2900
Bid3.0100 x 900
Ask0.0000 x 1800
Day's Range3.0000 - 3.2900
52 Week Range2.2000 - 15.8200
Volume220,282
Avg. Volume367,314
Market Cap12.99M
Beta (5Y Monthly)1.02
PE Ratio (TTM)N/A
EPS (TTM)-6.1060
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est7.50
  • Intec Pharma Reports Third Quarter 2020 Financial Results and Provides Corporate Update
    PR Newswire

    Intec Pharma Reports Third Quarter 2020 Financial Results and Provides Corporate Update

    Intec Pharma Ltd. (NASDAQ: NTEC) ("Intec" or "the Company") today announces financial results for the third quarter ended September 30, 2020 and provides a corporate update.

  • Intec Pharma Announces 1-for-20 Reverse Share Split
    PR Newswire

    Intec Pharma Announces 1-for-20 Reverse Share Split

    Intec Pharma Ltd. (NASDAQ: NTEC) ("Intec" or "the Company") today announces a 1-for-20 reverse share split of its outstanding ordinary shares. The reverse share split is scheduled to become effective after trading closes on October 29, 2020, and the Company's ordinary shares will begin trading on a split-adjusted basis on the Nasdaq Capital Market at the commencement of trading on October 30, 2020 under the Company's existing symbol "NTEC." The Company's ordinary shares have been assigned a new CUSIP number of M53644148 in connection with the reverse share split. As previously disclosed, at the Company's Annual Meeting of Shareholders held on July 15, 2020, the Company's shareholders approved a proposal to amend the Company's Articles of Association to effect a reverse share split of the Company's ordinary shares at a ratio with the range from 1-for-5 to 1-for-25, to be effective at the ratio and on a date to be determined by the Company's board of directors in its sole discretion.

  • Intec Pharma Announces New Research Collaboration Agreement with MSD
    PR Newswire

    Intec Pharma Announces New Research Collaboration Agreement with MSD

    Intec Pharma Ltd. (NASDAQ: NTEC) ("Intec" or "the Company") today announces it has entered into a new research collaboration agreement with MSD, the tradename of Merck & Co., Inc., Kenilworth, NJ, USA. Details of the agreement are confidential.